Skip to main content
MedVellum
QuestionsVideosPricing

MedVellum

Fellowship exam preparation across every specialty: source-verified topics, questions in every format, and videos.

Product

  • Specialties
  • Questions
  • Videos
  • Exam tools
  • Pricing

Verification & policy

  • Verified register
  • Editorial policy
  • Privacy
  • Terms

Account

  • Sign in
  • Create account
  • Dashboard
  • Account & billing

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

llms.txtPsychiatry LLM catalogSitemap

O&G SAQsGynaecological oncology — survivorship and MDT working

O&G SAQs · Gynaecological oncology — survivorship and MDT working

Survivorship and MDT working — structured SAQ (15 marks)

FRANZCOG-format structured SAQ on gynaecological cancer survivorship: survivorship care plan components, the sexual-function restorative ladder (moisturiser/lubricant, topical vaginal oestrogen, dilator with adherence, physiotherapy, sex therapy), evidence-based surveillance and the questioning of the routine pelvic examination, and management of fear of cancer recurrence and distress. Per-sub-part marking rubric included.

15 marks20 min3 min readVerification in progress

Target exams

FRANZCOGMRCOGABOGFRCSCMRCPI
On this page
Study tools

Target exams

FRANZCOGMRCOGABOGFRCSCMRCPI
Prompt
You are the gynaecology registrar running a survivorship clinic. A 49-year-old woman completed concurrent chemoradiotherapy for FIGO 2018 stage IIB cervical cancer eleven months ago. Her surveillance vault review, pelvic MRI and PET-CT are clear. She volunteers — only when asked — that intercourse has become too painful to continue, that her left leg aches and swells by evening, that she wakes drenched in sweat, and that she is convinced every twinge is the cancer returning. (a) Define what a survivorship care plan must contain, and state why giving it to the patient and her GP matters. (3 marks) (b) Outline your assessment and management of her sexual dysfunction, naming the restorative ladder in order with the rationale for each step. (5 marks) (c) She asks why she has to keep coming to clinic for pelvic examinations when her scans are normal. Using the evidence, explain how surveillance should be structured for gynaecological cancer recurrence and the limitations of routine pelvic examination. (4 marks) (d) Describe your management of her fear of cancer recurrence and distress. (3 marks)

How this SAQ is marked

Marks come from specifics: named components, named steps with rationale, named trial findings, and the precise surveillance reasoning. Write in short labelled points. This survivorship question is graded on whether you deliver surveillance and late-effect management and psychosocial support in one coordinated plan — not vault smears alone. [1]

Reveal model answer and mark schemeShowHide

(a) Survivorship care plan contents and delivery (3 marks)

One mark for listing components (at least four named), one for naming follow-up/late-effect content, one for the delivery principle. [1]

  • Diagnosis and staging, treatments received (surgery extent, radiotherapy site/dose/brachytherapy, chemotherapy agents and cumulative doses), the surveillance schedule, the late and long-term effects to monitor, psychosocial resources, the named follow-up provider and shared-care arrangements, and health promotion (exercise, weight, smoking, bone health).[1]
  • Delivery matters: a written copy goes to the patient and her general practitioner, with a named pathway back into specialist care — a plan that lives only in the oncology file has failed.[1]

(b) Sexual dysfunction — assessment and the restorative ladder (5 marks)

One mark for permission-giving assessment (FSFI), one for non-hormonal first-line, one for topical vaginal oestrogen, one for dilator with adherence, one for physiotherapy/sex therapy referral. [2]

  • Assess first with permission-giving language ("Many women notice changes after this treatment…"), because dysfunction is prevalent but under-reported unless invited; objectify with the Female Sexual Function Index if needed. Mechanism is radiotherapy-induced epithelial atrophy and fibrosis producing stenosis, shortening and loss of lubrication.[2]
  • Non-hormonal first: vaginal moisturiser for atrophy, lubricant for activity.[2]
  • Topical vaginal oestrogen for atrophy and as part of prevention regimens (studied in the Martins randomised clinical trial of dilator and topical agents for stenosis prevention after cervical radiotherapy).[3]
  • Vaginal dilator therapy to prevent and treat stenosis, started during or soon after radiotherapy, used regularly (several times weekly) and long-term — adherence is the rate-limiting step (Law prospective study).[4]
  • Pelvic floor physiotherapy for hypertonicity and pain, and psychological/sex therapy referral — do not abandon the patient once the physical prescription is written.[2][4]

(c) Evidence-based surveillance and the limits of the pelvic exam (4 marks)

One mark for the purpose of surveillance, one for symptom/marker/imaging as detection, one for the ovarian-cancer pelvic-exam finding, one for patient-initiated follow-up in endometrial cancer. [5]

  • Surveillance exists to detect treatable recurrence early, to reassure, and to manage late effects — in tension, because over-surveillance has harms (false positives, cumulative radiation, anxiety).[5]
  • Most recurrences are detected by symptoms, tumour markers and imaging, not the ritual pelvic examination alone.[5]
  • In ovarian cancer, a retrospective series (Holtzman) found most patients were asymptomatic at the time recurrence was detected, and the pelvic examination was not the primary means of detection — the authors conclude the utility of routine surveillance visits and the pelvic exam should be re-examined.[5]
  • In early-stage endometrial cancer, a randomised trial (Jeppesen, BJOG 2018) showed patient-initiated follow-up was feasible and potentially cost-reducing, though hospital-based follow-up alleviated fear of recurrence to a slightly greater degree — so low-risk survivors can be managed with patient-initiated pathways supported by clear re-presentation advice.[6]

(d) Fear of cancer recurrence and distress (3 marks)

One mark for naming fear of recurrence as the driver, one for the distress thermometer screen, one for the management plan. [7]

  • Name it: fear of cancer recurrence is near-universal and is the single biggest driver of surveillance demand — no number of normal scans will treat the underlying fear.[6]
  • Screen with the Distress Thermometer (paired with the Impact Thermometer in Akizuki's work), repeated at visits; a positive screen triggers structured psychological assessment.[7]
  • Manage by acknowledging and normalising the fear, giving a specific written re-presentation plan ("if you develop new bleeding, constant pelvic pain, blood in your urine or a swollen leg, contact the clinic — don't wait"), offering structured psychological therapies for entrenched fear, and treating comorbid anxiety or depression.[6]
Obstetrics & Gynaecology Pro

Continue reading

You have read the opening of this SAQ. The complete unit — every section and its primary-source references — is part of the Obstetrics & Gynaecology fellowship library.

Sign in to continueSee pricing
References7ShowHide
  1. [1]Mayer DK, Nekhlyudov L, Snyder CF, et al. American Society of Clinical Oncology clinical expert statement on cancer survivorship care planning J Oncol Pract, 2014.PMID 25316025
  2. [2]Hathout L, Zhang Y, Lymberis S, et al. A Systematic Review of Patient-Reported Outcomes on the Impact of Radiation Therapy on Sexual Health in Patients With Gynecologic Cancer Int J Radiat Oncol Biol Phys, 2026.PMID 41720168
  3. [3]Martins J, Vaz AF, Grion RC, et al. Topical estrogen, testosterone, and vaginal dilator in the prevention of vaginal stenosis after radiotherapy in women with cervical cancer: a randomized clinical trial BMC Cancer, 2021.PMID 34112100
  4. [4]Law E, Kelvin JF, Thom B, et al. Prospective study of vaginal dilator use adherence and efficacy following radiotherapy Radiother Oncol, 2015.PMID 26164775
  5. [5]Holtzman S, Gellman C, Chess I, et al. Surveillance Visits for Ovarian Cancer: Is It Time to Reconsider? J Surg Oncol, 2025.PMID 40990395
  6. [6]Jeppesen MM, Jensen PT, Hansen DG, et al. Patient-initiated follow up affects fear of recurrence and healthcare use: a randomised trial in early-stage endometrial cancer BJOG, 2018.PMID 29978593
  7. [7]Akizuki N, Yamawaki S, Akechi T, et al. Development of an Impact Thermometer for use in combination with the Distress Thermometer as a brief screening tool for adjustment disorders and/or major depression in cancer patients J Pain Symptom Manage, 2005.PMID 15652442
Obstetrics & Gynaecology Pro

$29/ monthor $279 / year

The complete Obstetrics & Gynaecology library, every exam format, one subscription.

  • Complete library for one chosen specialty
  • Timed MCQ mock exams and spaced review
  • Clinical cases & cross-table vivas
See pricingSign in
PreviousSurgical positioning and nerve injuries — structured SAQ (15 marks)Perioperative care — positioning and nerve injuriesNextSurvivorship, MDT working and the generalist's role — structured SAQ (15 marks)Gynaecological oncology — survivorship